DiAs Web Monitoring: A Real-Time Remote Monitoring System Designed for Artificial Pancreas Outpatient Trials

Background: Developments in an artificial pancreas (AP) for patients with type 1 diabetes have allowed a move toward performing outpatient clinical trials. “Home-like” environment implies specific protocol and system adaptations among which the introduction of remote monitoring is meaningful. We present a novel tool allowing multiple patients to monitor AP use in home-like settings. Methods: We investigated existing systems, performed interviews of experienced clinical teams, listed required features, and drew several mockups of the user interface. The resulting application was tested on the bench before it was used in three outpatient studies representing 3480 h of remote monitoring. Results: Our tool, called DiAs Web Monitoring (DWM), is a web-based application that ensures reception, storage, and display of data sent by AP systems. Continuous glucose monitoring (CGM) and insulin delivery data are presented in a colored chart to facilitate reading and interpretation. Several subjects can be monitored simultaneously on the same screen, and alerts are triggered to help detect events such as hypoglycemia or CGM failures. In the third trial, DWM received approximately 460 data per subject per hour: 77% for log messages, 5% for CGM data. More than 97% of transmissions were achieved in less than 5 min. Conclusions: Transition from a hospital setting to home-like conditions requires specific AP supervision to which remote monitoring systems can contribute valuably. DiAs Web Monitoring worked properly when tested in our outpatient studies. It could facilitate subject monitoring and even accelerate medical and technical assessment of the AP. It should now be adapted for long-term studies with an enhanced notification feature.

[1]  Giordano Lanzola,et al.  A generic telemedicine infrastructure for monitoring an artificial pancreas trial , 2013, Comput. Methods Programs Biomed..

[3]  L. Magni,et al.  Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the Results , 2010, Journal of diabetes science and technology.

[4]  Giordano Lanzola,et al.  Bringing the Artificial Pancreas Home: Telemedicine Aspects , 2011, Journal of diabetes science and technology.

[5]  Lutz Heinemann,et al.  Comparison of the Numerical and Clinical Accuracy of Four Continuous Glucose Monitors , 2008, Diabetes Care.

[6]  Towards an artificial pancreas at home. , 2011, Diabetes & metabolism.

[7]  G. Charpentier,et al.  The Diabeo Software Enabling Individualized Insulin Dose Adjustments Combined With Telemedicine Support Improves HbA1c in Poorly Controlled Type 1 Diabetic Patients , 2011, Diabetes Care.

[8]  Howard C. Zisser,et al.  Feasibility of Outpatient Fully Integrated Closed-Loop Control , 2013, Diabetes Care.

[9]  Eyal Dassau,et al.  Modular artificial beta-cell system: a prototype for clinical research. , 2008, Journal of diabetes science and technology.

[10]  L. Magni,et al.  Model Predictive Control of Type 1 Diabetes: An in Silico Trial , 2007, Journal of diabetes science and technology.

[11]  J. Stockman,et al.  Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial , 2011 .

[12]  Eyal Dassau,et al.  Zone Model Predictive Control: A Strategy to Minimize Hyper- and Hypoglycemic Events , 2010, Journal of diabetes science and technology.

[13]  Lutz Heinemann,et al.  AP@home: A Novel European Approach to Bring the Artificial Pancreas Home , 2011, Journal of diabetes science and technology.

[14]  R. Hovorka,et al.  Nonlinear model predictive control of glucose concentration in subjects with type 1 diabetes. , 2004, Physiological measurement.

[15]  C. Cobelli,et al.  Artificial Pancreas: Past, Present, Future , 2011, Diabetes.

[16]  Eyal Dassau,et al.  Modular Artificial β-Cell System: A Prototype for Clinical Research , 2008 .

[17]  Moshe Phillip,et al.  Feasibility study of automated overnight closed-loop glucose control under MD-logic artificial pancreas in patients with type 1 diabetes: the DREAM Project. , 2012, Diabetes technology & therapeutics.

[18]  Thomas Danne,et al.  Advanced Technologies and Treatments for Diabetes , 2012 .

[19]  Eyal Dassau,et al.  Pilot Studies of Wearable Outpatient Artificial Pancreas in Type 1 Diabetes , 2012, Diabetes Care.

[20]  G. Charpentier,et al.  The Diabeo Software Enabling Individualized Insulin Dose Adjustments CombinedWith Telemedicine Support Improves HbA 1 c in Poorly Controlled Type 1 Diabetic Patients A 6-month , randomized , open-label , parallel-group , multicenter trial ( TeleDiab 1 Study ) , 2011 .

[21]  G. Steil,et al.  Feasibility of Automating Insulin Delivery for the Treatment of Type 1 Diabetes , 2006, Diabetes.

[22]  Michael D. Skillen,et al.  A diabetes management system empowering patients to reach optimised glucose control: From monitor to advisor , 2010, 2010 Annual International Conference of the IEEE Engineering in Medicine and Biology.

[23]  S. Patek,et al.  Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: The Virginia Experience , 2009, Journal of diabetes science and technology.

[24]  Howard Zisser,et al.  OmniPod Insulin Management System , 2006, Diabetes Care.

[25]  D. Klonoff Continuous glucose monitoring: roadmap for 21st century diabetes therapy. , 2005, Diabetes care.

[26]  L. Magni,et al.  Closed-Loop Artificial Pancreas Using Subcutaneous Glucose Sensing and Insulin Delivery and a Model Predictive Control Algorithm: Preliminary Studies in Padova and Montpellier , 2009, Journal of diabetes science and technology.